Table 3.

Blood parameters at baseline and after gonadotropin releasing hormone antagonist alone and with concurrent placebo or estradiol add-back treatment in premenopausal (Pre), perimenopausal (Peri), and postmenopausal (Post) women

	Placebo			Estradiol
Parameters	Pre	Peri	Post	Pre	Peri	Post
n	12	21	13	12	17	12
TAS, nmol/L
Baseline	1.4±0.2	1.3±0.1	1.3±0.2	1.4±0.2	1.3±0.2	1.3±0.2
GnRHant	1.5±0.1	1.3±0.1	1.4±0.3	1.4±0.2	1.3±0.2	1.3±0.1
GnRHant+Add-back	1.4±0.1	1.3±0.1	1.3±0.2	1.4±0.1	1.3±0.1	1.3±0.2
IL-6, pg/mLa
Baseline	0.7(0.6-1.3)	0.8(0.6-1.3)	0.8(0.6-1.2)	0.8(0.5-1.3)	0.8(0.5-1.3)	0.9(0.6-1.8)
GnRHant	0.9(0.6-1.1)	1.1(0.6-1.3)	1.0(0.8-1.6)	0.7(0.5-1.1)	1.1(0.8-1.5)	0.9(0.7-1.8)
GnRHant+Add-back	0.8(0.6-1.4)	1.0(0.7-1.1)	1.1(0.8-1.5)	0.9(0.7-1.9)	1.1(0.7-1.4)	1.2(0.8-2.1)
CRP, mg/La
Baseline	0.7(0.3-3.7)	0.9(0.5-1.9)	1.1(0.8-1.4)	0.7(0.3-2.3)	0.9(0.5-1.5)	1.1(0.3-3.9)
GnRHant	0.8(0.4-4.2)	0.9(0.5-1.6)	1.3(0.7-2.1)	1.2(0.5-2.2)	0.9(0.6-2.2)	1.4(0.3-3.8)
GnRHant+Add-back	0.7(0.3-3.3)	1.0(0.5-1.4)	1.1(0.7-2.2)	1.1(0.3-2.6)	0.9(0.6-1.8)	1.5(0.5-4.0)
ET-1, pg/mL b
Baseline #	5.2±0.9	6.2±1.6	6.4±1.1	5.2±1.5	5.9±1.3	6.2±1.4
GnRHant	5.5±0.9	5.9±0.9	6.5±0.9	5.5±1.7	6.0±1.8	6.5±2.1
GnRHant+Add-back	5.0±0.7	5.7±1.9	6.4±0.9	6.0±1.1	5.9±1.6	6.0±1.8
Norepinephrine, pg/mLa
Baseline #	184(101-217)	247(164-295)	242(228-331)	161(108-230)	227(168-280)	231(127-349)
GnRHant	156(103-252)	233(159-341)	217(180-282)	144(116-164)	235(183-282)	380(156-362)
GnRHant+Add-back	158(111-229)	217(152-282)	221(162-303)	146(118-214)	231(168-295)	204(168-280)

Values are mean ± SD, unless otherwise indicated. ^a Values are median (interquartile range). ^b n=84 # P < 0.05 main effect of menopause stage. GnRHant gonadotropin releasing hormone antagonist; TAS total antioxidant status; IL-6 interluekin-6; CRPC-reactive protein; ET-1 endothelin-1